Personalized Psychiatry

Global Personalized Psychiatry Market to Reach US$7.5 Billion by 2030

The global market for Personalized Psychiatry estimated at US$4.4 Billion in the year 2024, is expected to reach US$7.5 Billion by 2030, growing at a CAGR of 9.3% over the analysis period 2024-2030. Products, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Services segment is estimated at 10.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 12.6% CAGR

The Personalized Psychiatry market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.

Global Personalized Psychiatry Market – Key Trends & Drivers Summarized

How Is the Shift Toward Precision Mental Health Transforming the Practice of Psychiatry?

Personalized psychiatry, also known as precision psychiatry, is redefining the landscape of mental health treatment by leveraging genetic, neurobiological, and environmental data to guide individualized care. Traditional psychiatric treatment has long struggled with variability in drug efficacy, trial-and-error prescriptions, and poorly understood diagnostic boundaries. Personalized psychiatry seeks to overcome these limitations through biomarker-based diagnosis, pharmacogenomic testing, and neuroimaging-guided treatment planning—offering the potential to match the right intervention to the right patient at the right time.

Growing evidence in neuroscience and genomics is enabling more targeted approaches to disorders such as depression, schizophrenia, bipolar disorder, and anxiety. Tools like polygenic risk scores, EEG-based pattern recognition, and machine learning models are increasingly being integrated into psychiatric evaluations. These advancements are improving diagnostic accuracy, reducing adverse drug reactions, and enhancing therapeutic outcomes—particularly in patients with treatment-resistant conditions or comorbidities.

Why Are Pharmacogenomics and Digital Phenotyping Reshaping Psychiatric Intervention Strategies?

Pharmacogenomics has become a cornerstone of personalized psychiatry, offering clinicians actionable insights into how individual genetic profiles influence responses to psychiatric medications. Commercially available gene panels now analyze variations in CYP450 enzymes, serotonin transporters, and other pharmacodynamic targets, guiding the selection and dosing of antidepressants, antipsychotics, and mood stabilizers. This approach minimizes side effects, speeds up therapeutic response, and reduces the burden of trial-based prescribing practices.

Simultaneously, digital phenotyping is gaining traction as a real-time, non-invasive tool for monitoring mood, cognition, and behavior through smartphone sensors, voice analysis, and wearable devices. These technologies generate continuous behavioral data that can detect early signs of relapse, measure treatment response, and support adaptive interventions. Integration of digital biomarkers into clinical workflows is enabling dynamic, data-driven psychiatry that moves beyond episodic consultations toward longitudinal, patient-specific care.

How Are Regulatory Bodies, Reimbursement Systems, and AI Tools Influencing Clinical Adoption?

Regulatory progress is catalyzing market maturity in personalized psychiatry. Agencies such as the FDA and EMA have begun approving pharmacogenomic-based drug labeling and companion diagnostics in psychiatric care. In the U.S., CMS has expanded coverage for select pharmacogenetic tests, while several private insurers are reimbursing validated gene panels in major depressive disorder. These policy developments are encouraging broader clinical uptake and investment in companion diagnostics and AI-powered decision support tools.

AI and machine learning are also facilitating more robust prediction models for mental health conditions, enabling early intervention and stratified risk profiling. These algorithms are being trained on multimodal datasets—including genomics, imaging, EHRs, and wearable outputs—to identify subtypes within traditional diagnostic categories. This nuanced understanding of psychiatric pathophysiology is guiding the development of targeted therapies and supporting the emergence of precision mental health platforms that integrate diagnostics, therapeutics, and patient monitoring in a closed-loop system.

What’s Driving the Global Growth of the Personalized Psychiatry Market?

The growth in the personalized psychiatry market is driven by several factors including the rising prevalence of mental health disorders, growing awareness of interindividual treatment variability, and the convergence of genomics, neuroimaging, and digital health technologies. A primary growth driver is the global shift toward value-based care and outcome-driven reimbursement, which favors precise and effective treatment strategies over broad-spectrum pharmacotherapy.

Expanding access to genomic testing, proliferation of digital health startups, and growing academic-industry collaborations are accelerating the commercialization of personalized psychiatric tools. Moreover, the societal cost of ineffective psychiatric care—reflected in lost productivity, relapse rates, and healthcare expenditures—is incentivizing stakeholders to adopt predictive, personalized treatment models. As research continues to validate biomarkers and refine classification systems, personalized psychiatry is poised to become a foundational component of next-generation mental health care.

SCOPE OF STUDY:

The report analyzes the Personalized Psychiatry market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Products, Services, Software); Therapeutic Area (Depression, Anxiety, Bipolar Disorder, Schizophrenia, Addiction, Other Therapeutic Areas)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• 23andMe
• AltheaDx, Inc.
• Arcara Personalized Psychiatry
• BrainsWay Ltd.
• BrightQuest Treatment Centers
• CBT Plus
• Genomind
• GreyBird Ventures
• HMNC Holding GmbH
• Karuna Therapeutics
• Mindstrong
• Myriad Genetics
• Peak Mental Wellness
• Pear Therapeutics
• Spring Health
• Starling Minds
• Sunovion Pharmaceuticals Inc.
• Tempus AI
• WayForward
• Woebot Health

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.